| Name | Title | Contact Details |
|---|---|---|
Edward Littlejohn |
Chief Operating Officer | Profile |
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.
SciLog is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lab Products is a Seaford, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Biocare is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capistrano Lab Inc is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.